

IMV represents an opportunity to invest in one of the most advanced and innovative immunotherapy and vaccine platforms in the world.

Company Overview

- IMV Inc., Immunovaccine Technologies Inc. and IMV USA Inc. (together “IMV” or the “Company”) is a **clinical-stage** biopharmaceutical Company developing a portfolio of immune-educating therapies based on its **novel DPX® platform** to better treat solid and hematologic cancer patients.
- Cancer immunotherapy is a type of treatment designed to leverage a patient’s own immune system to eradicate cancer cells. The DPX platform utilizes a **targeted delivery of therapeutic vaccination** that mimics the natural flow of antigens through the human immune system.
- DPX is a **versatile lipid-in-oil delivery technology** for delivery of single or multiple bioactive molecules, including peptides, whole proteins, RNA, DNA, small molecules, and virus-like particles.
- The Company’s lead DPX-based asset, **Maveropepimut-S (or MVP-S)**, has shown promising clinical activity and is primed for development towards registration through collaborations or partnerships.
- Initial results from the **MVP-S Phase 2B VITALIZE trial in DLBCL**, IMV’s most advanced and rigorous trial to date, have shown **confirmed clinical responses** in preliminary findings.

Sale and Investment Solicitation Process

- On May 1, 2023, IMV obtained protection from its creditors under the Companies’ Creditors Arrangement Act (“CCAA”). FTI Consulting Canada Inc. was appointed as Monitor (the “Monitor”).
- On May 5, 2023, the Nova Scotia Supreme Court approved a sale and investment solicitation process (“SISP”) to seek offers for the business, property, assets and undertaking of IMV. The SISP is being undertaken by the Monitor in conjunction with its affiliate, FTI Capital Advisors Canada.
- The SISP will solicit bids and proposals for a broad range of executable transaction alternatives, including: (i) a sale of assets and/or shares; (ii) restructuring; (iii) recapitalization; and (iv) refinancing of the IMV business.
- A transaction may involve a form of reorganization of the business, or certain assets of the business, resulting in a new capital structure pursuant to Court approval or a plan of compromise or arrangement in accordance with the CCAA.

Non-binding letter of intent submission deadline is 5:00 p.m. (Halifax Time) on June 19, 2023

Key Highlights



Intellectual Property

- 22 patent families containing 66 issued and 77 pending patents in 12 jurisdictions

Investments in Innovation

- Over \$125 million has been invested to-date



Leadership Team

- Strong leadership team with deep experience and accreditation in the pharmaceutical and biotechnology industries




Innovative Products and Techniques

- DPX® Platform – versatile delivery platform that is applicable to a variety of therapeutic areas outside of cancer treatment to mitigate and destroy disease
- MVP-S – DPX-based cancer vaccine targeting tumors associated with the surviving protein

DPX® Delivery Platform

DPX platform is a novel lipid-based vessel technology capable of delivering a wide range of bioactive molecules.



- DPX technology produces a **robust, targeted** and **long-lasting** anti-cancer immune response for the treatment of solid and hematologic malignancies.
- Practical Advantages of the DPX Delivery Platform:
 - **Long-acting delivery** → The lipid-in-oil formulation allows for the sustained availability of bioactive molecules, over time and does not leak cargo into surrounding tissue.
 - **Broad Therapeutic Application** → The lipids used in the DPX delivery platform allow it to package a variety of bioactive cargo in a single formulation (including peptides, whole proteins, RNA, DNA, small molecules, and VLPs).
 - **Physiologic Immune Activation** → The DPX delivery platform incites engulfment of its cargo, which in turn activates a specific immune response mediated by the lymph node. The introduction of cargo to the immune system in this manner, mimics the natural exposure of antigens to the immune system.
 - **Immune Cell Education** → By simultaneously delivering key stimulants to the immune system in a single formulation, DPX can induce the generation of robust, persistent and specific immune responses confirmed by specific cell activation in clinical studies.

IMV is developing a portfolio of DPX based immunotherapies which are being investigated in multiple solid and hematologic cancers. IMV aims to expand the DPX platforms potential to treat a broad range of cancers.

Clinical Research and Trial Highlights

IMV is building a pipeline of DPX-based immuno-oncology candidates. The clinical trials conducted to date support the therapeutic potential of the Company’s lead compound, MVP-S. Goals of advancing MVP-S toward registration trials are well underway.

DPX-Based Immunotherapy	Indication	Pre-Clinical	Phase 1	Phase 2	Phase 3	Collaborators
Maveropepimut-S (MVP-S)	DLBCL		Combination with Keytruda®			
	Ovarian Cancer					
	Bladder, Liver, MSI-H Tumors (Basket Trial)		Combination with Keytruda®			
	Breast Cancer		As neoadjuvant + aromatase inhibitor			
MVP-S and DPX-SurMAGE	Non-Muscle Invasive Bladder Cancer		As neoadjuvant			

- MVP-S is currently being evaluated in clinical trials for hematologic and solid cancers, including Diffuse Large B Cell Lymphoma as well as ovarian, bladder and breast cancers.
- More than 300 patients have received at least one dose of MVP-S in clinical trials. MVP-S has shown an exceptional safety profile as well as clinical responses (CRs, PRs, SD) in multiple cancer indications.
- The Company’s second immunotherapy product candidate, DPX-SurMAGE, a novel dual-targeted immunotherapy, has entered Phase 1 in usage against non-muscle invasive bladder cancer.

Contact Information

Parties interested in the opportunity will be asked to execute a non-disclosure agreement. All inquiries regarding a potential transaction and any request for additional information should be directed to one of the FTI Capital Advisors Canada contacts listed below and FTI Consulting Canada Inc. (the “Monitor”):

FTI Capital Advisors Canada		FTI Consulting Canada Inc.
<p>Dean Mullett Senior Managing Director 416.816.0733 dean.mullett@fticonsulting.com</p>	<p>Richard Kim Managing Director 647.330.5054 richard.kim@fticonsulting.com</p>	<p>Jeffrey Rosenberg Senior Managing Director 289.221.1684 jeffrey.rosenberg@fticonsulting.com</p>